Outsourcing Facility Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 rates for the establishment and reinspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities, as well as a reinspection fee for each reinspection of an outsourcing facility. This document establishes the FY 2027 rates for the small business establishment fee ($7,142), the non-small business establishment fee ($22,074), and the reinspection fee ($21,427) for outsourcing facilities; provides information on how the fees for FY 2027 were determined; and describes the payment procedures outsourcing facilities should follow.
Related coverage
- Statutorily Mandated Designation of Difficult Development Areas and Qualified Census Tracts for 2027
- Administrative Declaration of an Economic Injury Disaster for the State of Oregon
- Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information
- Reef Fish Fishery of the Gulf of America; Amendment 62
- Transparency in Coverage
- Adoption of Updated EDGAR Filer Manual